← Back to Search

GLP-1 Receptor Agonist

Semaglutide and Orforglipron for Type 2 Diabetes(ACHIEVE-3 Trial)

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, China
Orforglipron +1 morePhase 3RecruitingResearch Sponsored by Eli Lilly and Company

ACHIEVE-3 Trial Summary

This trial will compare a new diabetes drug with semaglutide to see if it's safe and effective for people with Type 2 diabetes who take metformin. The trial will last 61 weeks.

Eligible Conditions
  • Type 2 Diabetes

ACHIEVE-3 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Your HbA1c level is between 7.0% to 10.5%, as measured by the central laboratory during screening.
You have been taking at least 1500 mg of metformin every day for the past 90 days and will continue taking it during the study.
You have Type 2 diabetes.

ACHIEVE-3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Hemoglobin A1c (HbA1c)
Secondary outcome measures
Change from Baseline in Body Weight
Change from Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)
Change from Baseline in Diastolic Blood Pressure (DBP)
+17 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

ACHIEVE-3 Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Orforglipron Dose 2Experimental Treatment1 Intervention
Participants will receive orforglipron orally.
Group II: Orforglipron Dose 1Experimental Treatment1 Intervention
Participants will receive orforglipron orally.
Group III: Semaglutide Dose 1Active Control1 Intervention
Participants will receive semaglutide orally.
Group IV: Semaglutide Dose 2Active Control1 Intervention
Participants will receive semaglutide orally.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,565 Previous Clinical Trials
3,179,439 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,320 Previous Clinical Trials
397,993 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare facilities are administering this trial?

"Currently, 134 participants have enrolled in this clinical trial – these include the San Fernando Valley Health Institute of Canoga Park, Neighborhood Healthcare Institute of Escondido and Velocity Clinical Research Gardena. Additionally, there are other sites around the country."

Answered by AI

What potential adverse effects can be caused by administering Orforglipron Dose 1?

"Orforglipron Dose 1 has been proven safe in prior clinical studies, thus it was assigned a score of 3."

Answered by AI

Are there any remaining opportunities for individuals to partake in this research?

"The details posted on clinicaltrials.gov inform us that this study is not presently engaging in patient recruitment. It was initially featured on September 27th 2023 and last updated nine days later, but 1479 other trials are actively searching for candidates right now."

Answered by AI

Who else is applying?

What site did they apply to?
SKY Integrative Medical Center/SKYCRNG
New Phase Research and Development
Clear Brook Medical Associates
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
~1051 spots leftby Jul 2025